AI Article Synopsis
- Luxembourg's introduction of nirsevimab immunisation for RSV led to an impressive neonatal coverage of 84% in 2023.
- The number of paediatric RSV-related hospitalisations for infants under 6 months significantly decreased, dropping from 232 in 2022 to 72 in 2023.
- Additionally, hospital stays shortened and the average age of hospitalised children increased, indicating that nirsevimab effectively reduced severe RSV infections and lessened the burden on healthcare.
Article Abstract
After Luxembourg introduced nirsevimab immunisation against respiratory syncytial virus (RSV), estimated neonatal coverage was 84% (1,277 doses/1,524 births) in 2023. That year, paediatric RSV-related hospitalisations, especially concerning infants < 6 months old (n = 72) seemed to decrease compared to the same period in 2022 (n = 232). In 2023, hospitalised children's mean age increased (14.4 months vs 7.8 months in 2022; p < 0.001) and hospital-stay length decreased (3.2 days vs 5.1 days; p < 0.001). In infants < 6 months old, intensive-care unit admissions appeared to drop (n = 28 vs 9). This suggests that nirsevimab prophylaxis reduced severe RSV infections, particularly in infants < 6 months old, thereby alleviating healthcare strain.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986653 | PMC |
| http://dx.doi.org/10.2807/1560-7917.ES.2024.29.4.2400033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!